期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

左西孟旦对急性冠脉综合征合并急性心力衰竭的作用研究现况 被引量：5

Research Status on Effect of Levosimendan in Acute Coronary Syndrome Complicated with Acute Heart Failure
下载PDF
导出
摘要 急性冠脉综合征会出现急性心肌缺血、心功能受损和心律失常,进而导致急性心力衰竭的发生。而急性心力衰竭又反过来使得急性冠脉综合征的病情变得更加复杂,在治疗过程中,往往需要正性肌力药物来控制病情。而传统的正性肌力药物会增加心肌耗氧量,反而增加患者死亡率。近几年来,左西孟旦作为一种不增加心肌耗氧的钙增敏剂应运而生。根据许多研究,它已被认为适合用于急性冠脉综合征导致的急性心力衰竭患者中。并逐渐发现,左西孟旦除了"钙增敏"作用之外,还有其他的有助于病情改善的作用。现综述目前为止关于左西孟旦在急性冠脉综合征合并急性心力衰竭中作用机制和疗效评价的研究报道,旨在能更加全面地认识该药物在急性冠脉综合征合并急性心力衰竭中的作用并为进一步挖掘其潜能提供思路。 Acute coronary syndrome （ACS） can cause acute myocardial ischemia, impairment of heart function,and aixhythmia, which lead to acute heart failure（AHF）. AHF, in turn, makes the condition of ACS more complicated. The positive inotropic drugs are often needed to control the illness during the process of treatment. The traditional inotropic agents will increase myocardial oxygen consumption,and improve the mortality. Levosimendan,as a calcium sensitizer,which is a inotropic effect that does not increase myocardial oxygen consumption,came into being in recent years. According to many studies,it has been thought to be suitable for patients with AHF caused by ACS. Nowadays,people have gradually found that in addition to “calcium sensitization” of levosimendan,there are other factors that help to improve the condition. This review summarizes the reports so far on the mechanism and efficacy of levosimendan in the treatment of ACS complicated with AHF,so that people can fully understand the role of levosimendan in ACS complicated with AHF and provide ideas for further exploring of its potential.
作者 孟祥旭 滕伟 惠学志 MENG Xiangxu;TENG bei;HUI Xuezhi(Department of Cardiology,The First Affiliated Hospital of Henan University,Kaifeng 415000,Henan,China)
机构地区 河南大学第一附属医院心血管内科
出处 《心血管病学进展》 CAS 2018年第3期394-397,共4页 Advances in Cardiovascular Diseases
关键词 左西孟旦 急性冠脉综合征 急性心力衰竭 Levosimendan Acute coronary syndrome Acute heart failure
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献1

二级参考文献54

  • 1Abraham, W.T., Adams, K.F., Fonarow, G.C., Costanzo, M.R., Berkowitz, R.L., LeJemtel, T.H., Cheng, M.L., Wynne, J., 2005. In-hospital mortality in patients with acute de- compensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J. Am. Coll. Cardiol., 46(1):57-64. [cloi:50.10]6/j.jacc.2005.03.051].
  • 2Adamopoulos, S., Parissis, J.T., Iliodromitis, E.K., Paraskevaidis, 1., Tsiapras, D., Farmakis, D., Karatzas, D., Gheorghiade, M., Filippatos, G.S., Kremastinos, D.T., 2006. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am. J. Cardiol., 98(1):102-106. [doi:10. 1016/j.amjcard.2006.01.068).
  • 3Alhashemi, J.A., Alotaibi, Q.A., Abdullah, G.M., Shalabi, S.A., 2009. Levosimendan vs dobutamine in septic shock. J. Crit. Care, 24(3):e 14. [doi: 10.1016/j.jcrc.2009.06.006).
  • 4Alvarez, J., Taboada, M., Rodriguez, J., Caruezo, V., Bouzada, M., Campana, 0., Bascuas, B., Perez-Paz, J., Gincsta, V., 2005. Hemodynamic effects of levosimendan following cardiac surgery. Rev. Esp. Anestesiol. Reanim., 52(7): 389-394.
  • 5Alvarez, J., Bouzada, M., Fernandez, A.L., Caruezo, V., Taboada, M., Rodriguez, J., Ginesta, V., Rubio, J., Garcia-Bengoechea, J.B., Gonzalez-Juanatey, lR., 2006. Hemodynamic effects of levosimendan compared with dobutamine in patients with low cardiac output after cardiac surgery. Rev. Esp. Cardio/', 59(4):338-345 (in Spanish). [doi: 1 0.1157/13087055].
  • 6Bayram, M., de Luca, L., Massie, M.B., Gheorghiade, M., 200S. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am. J. Cardiol., 96(6A):47G-S8G. [doi:10. 1016/j.amjcard.2005.07.021].
  • 7Bergh, C.H., Andersson, B., Dahlstrom, U., Forfang, K., Kivikko, M., Sarapohja, T., Ullman, B., Wikstrom, G., 2010. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on ~-blockers. Eur. J. Heart Fail., 12(4):404-410. [doi:10.1093/eurjhflhfq032].
  • 8Bonios, M.J., Terrovitis, J.V., Drakos, S.G., Katsaros, F., Pantsios, c., Nanas, S.N., Kanakakis, 1., Alexopoulos, G., Toumanidis, S., Anastasiou-Nana, M., et al., 2012. Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure. Int. J. Cardiol., 159(3):22S-229. [doi:10.1016/j.ijcard.2011.03.013].
  • 9Cleland, J.G.F., Freemantle, N., Coletta, A.P., Clark, A.L., 2006. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur. J. Heart Fail., 8(1): lOS-I 10. [doi:10.1016/j.ejheart.2005.12.003].
  • 10Costanzo, M.R., Johannes, R.S., Pine, M., Gupta, V., Saltzberg, M., Hay, J., Yancy, C.W., Fonarow, G.C., 2007. The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database. Am. Heart J., 154(2):267-277. [doi:10.1016/j.ahj.2007.04.033].

共引文献6

同被引文献64

二级引证文献16

心血管病学进展
2018年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部